Alpha-Fetoprotein, Stem Cells and Cancer: How Study of the Production of Alpha-Fetoprotein during Chemical Hepatocarcinogenesis Led to Reaffirmation of the Stem Cell Theory of Cancer

Stewart Sell

Wadsworth Center and Ordway Research Institute, Albany, N.Y., USA

Key Words

α -Fetoprotein · Stem cells · Cancer · Alpha-fetoprotein

Abstract

Identification of the cells in the liver that produce α -fetoprotein during development, in response to liver injury and during the early stages of chemical hepatocarcinogenesis led to the conclusion that maturation arrest of liver-determined tissue stem cells was the cellular process that gives rise to hepatocellular carcinomas. When the cellular changes in these processes were compared to that of the formation of teratocarcinomas, the hypothesis arose that all cancers arise from maturation arrest of tissue-determined stem cells. This was essentially a reinterpretation of the embryonal rest theory of cancer whereby tissue stem cells take the role of embryonal rests. A corollary of the stem cell theory of the origin of cancer is that cancers contain the same functional cell populations as normal tissues: stem cells, transit-amplifying cells and mature cells. Cancer stem cells retain the essential feature of normal stem cells: the ability to self-renew. Growth of cancers is due to continued proliferation of cancer transit-amplifying cells that do not differentiate to mature cells (maturation arrest). On the other hand, cancer stem cells generally divide very rarely and contribute little to tumor growth. However, the presence of cancer stem cells in tumors is believed to be responsible for the properties of immortalization, transplantability and resistance to therapy characteristic of cancers. Current therapies for cancer (che-

motherapy, radiotherapy, antiangiogenesis and differentiation therapy) are directed against the cancer transit-amplifying cells. When these therapies are discontinued, the cancer reforms from the cancer stem cells. Therapy directed toward interruption of the cell signaling pathways that maintain cancer stem cells could lead to new modalities to the prevention of regrowth of the cancer.

Copyright © 2008 S. Karger AG, Basel

Introduction

The goal of this review is to show how analysis of the production of α -fetoprotein (AFP) during normal development, after liver injury, during growth of hepatocellular carcinoma (HCC) and during the premalignant stages of chemical hepatocarcinogenesis led to reestablish-

The Abbot Award Lecture, presented at the 35th Meeting of the International Society for Oncodevelopmental Biology and Medicine, Prague, Czech Republic, September 17, 2007. This paper reviews the data from Dr. Sell's laboratory testing the hypothesis that liver cancer is due to dedifferentiation of mature cells. These data did not support this hypothesis. For detailed historical reference citations to α -fetoprotein and carcinogenesis, see Sell [Cell Sci Rev 2006;3:302–341]; for extensive citations on the biological properties of α -fetoprotein, see Mizejewski [Exp Biol Med 2004;229:430–463]. Dedicated to Garri Israelevich Abelev on the occasion of his 80th birthday, January 10, 2008.

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2008 S. Karger AG, Basel
1010–4283/08/0293–0161\$24.50/0

Accessible online at:
www.karger.com/tbi

Stewart Sell, MD
Wadsworth Center and Ordway Research Institute
Empire State Plaza
Albany, New York, NY (USA)
Tel. +1 518 474 0547, Fax +1 518 473 2900, E-Mail ssell@wadsworth.org

ment of the stem cell theory of cancer. The story begins with the discovery of AFP as a protein present not only in fetal serum [1–3], but also in the serum of both experimental animals [4] and humans [5] with HCC. Although a fetal serum protein, consistent with the properties of AFP, had been reported earlier [1–3], the papers by Abelev et al. [4] and Tatarinov [5] were the first to show the commonality of the protein produced by developing fetuses and adult tumors. The discovery of this protein, along with that of carcinoembryonic antigen [6], initiated the field of investigation that became known as ‘oncodevelopmental biology’ [7], a term linking the process of carcinogenesis to developmental biology. This conceptualization had been previously formulated by Pierce et al. [8] as: ‘cancer is a problem of developmental biology’.

The studies to be reviewed here began when the author joined the Department of Pathology at the University of Pittsburgh in 1965. The cellular and biochemical changes that preceded the development of HCC during experimental chemical hepatocarcinogenesis were under active investigation by the Chairman of the Department, Prof. Emmanuel Farber, and his collaborators. These studies were directed toward the examination of focal changes in small groups of liver cells (foci), and the development of nodules of increasing size that became known as ‘neoplastic nodules’ that appear in the livers of rats exposed to chemical hepatocarcinogens months before the eventual development of HCC [9, 10]. These changes implied that HCC arose by ‘dedifferentiation’ of adult hepatocytes. Since it had been shown (see above) that AFP was produced by HCC, the question that required answering was: Can the nature of the cells in the liver that give rise to HCC be clarified by analysis of the production of AFP during the carcinogenic process?

Radioimmunoassay for AFP

To address this question, the first objective was to develop a more sensitive and reproducible assay for AFP. I decided that a radioimmunoassay (RIA) for AFP would be the method of choice. RIA is up to 100 times more sensitive than the immunodiffusion assays that were then being used. Fortunately, I was not only taught the principles of RIA, but also had been required to develop an RIA for albumin by Richard S. Farr, as part of the sophomore microbiology laboratories in medical school in 1958. Farr published his extensive studies on antigen-antibody binding and RIA at about the same time [11]. This was 2 years before the paper on RIA for insulin was pub-

Fig. 1. Immunoelectrophoretic identification of AFP. To produce antiserum to AFP, rabbits were immunized with rat amniotic fluid and the anti-rat amniotic fluid serum was absorbed with normal adult rat serum. Later, AFP was isolated by isoelectric focusing and a specific antiserum was obtained by immunization of a goat with purified AFP (anti- α_1 F). CARS = Croton oil-induced acute-phase rat serum (contains α_1 -macroglobulin, α M-F); AMF = rat amniotic fluid; abs = absorbed; NARS = normal adult rat serum; TR = transferrin; γ G = γ -globulin; FRS = fetal rat serum. Modified from Sell et al. [15].

lished [12], for which the principal author, Rosalyn Yalow, received the Nobel Prize.

Using the methods recorded in my microbiology laboratory notebook, I developed an RIA for rat AFP [13]. To accomplish this, it was first necessary to identify and isolate AFP. From the previous studies of Gitlin et al. [14] it was known that amniotic fluid was a rich source of AFP. An antiserum that would specifically identify rat AFP was made by first immunizing rabbits with rat amniotic fluid, and then absorbing this antiserum with normal rat serum (fig. 1) [14]. Then, AFP was isolated by isoelectric focusing, but this method was adopted only after other methods had proven ineffective [15]. Because of difficulties in isolating pure AFP, it took over 5 years to establish the RIA for AFP. During this time period, several others published RIAs for both the human [16, 17] and rat [18, 19] isoforms of AFP. Before RIA was available, it was not known whether AFP was present in normal adult serum. With the application of the highly sensitive RIA, it became possible to measure normal levels of AFP accurately and reproducibly both in humans [16] and rats [20] (fig. 2).

Once our RIA for AFP was available, it was applied to measure the serum concentrations of AFP of the rat in normal development, after liver injury, following growth of transplantable HCC and during the hepatocarcino-

Fig. 2. RIA for rat AFP. **a** Standard curves for the 'high' and the 'low' RIA. The low assay was performed by preincubation of the unknown or the known standard with the anti-AFP before addition of the radiolabeled AFP. **b** The top of the figure shows the

range of AFP levels in normal rat serum. The bottom of the figure shows results of replicated assays for selected samples for normal rat serum. Each symbol represents the assays for a given serum. Modified from Sell and Gord [20].

genic process. The results are summarized in figure 3 [21]. During normal pregnancy in the rat, the level of AFP is 2 logs higher in fetal serum at term than in the mother. After birth, the serum level of AFP falls exponentially in the mother, but remains high for 3–4 weeks in the neonatal pup. There is a rapid but temporary elevation after liver injury. Following partial hepatectomy (PH), the serum level is higher in young rats than in older rats. The serum level is also higher after chemical injury than after PH. There is a steady, essentially logarithmic, increase during growth of a transplanted HCC, and a logarithmic decrease after surgical removal of the AFP-producing HCC, but reelevation is seen if the tumor is not fully removed or recurs as metastases. There is a prolonged elevation after treatment with a noncarcinogenic dose, for example a single cycle, of the carcinogen N-2-actylaminofluorine (AAF). These data illustrate the complexity of the production of AFP associated with various physiological and pathological conditions. The examples of elevation of serum AFP during normal development, after acute liver injury and growth of HCC as well as after exposure to chemical hepatocarcinogens, and the nature of the cells that produce AFP will now be presented in more detail.

AFP in Normal Development

During normal development, AFP is synthesized in the fetal yolk sac endoderm and liver, and then diffuses rapidly into the maternal circulation. Using incorporation of radioactive arginine into cells of various organs, we found that the major sites of synthesis are the yolk sac and liver, with a much lower production in the intestines [22]. This pattern was confirmed by Rot analysis for messenger RNA for AFP (mRNA_{AFP}) [23] and by in situ hybridization in collaboration with the late Jose Sala-Trepat (fig. 4). Using radiolabeled proteins injected into various fetal and maternal compartments, we found there to be a rapid equilibration of the labeled proteins in the fetal-maternal unit (fig. 5a) [24]. Both mRNA_{AFP} and $\text{mRNA}_{\text{albumin}}$ are present in high amounts in the liver during late fetal life, but $\text{mRNA}_{\text{albumin}}$ is not found in the yolk sac (fig. 5b) [25]. After birth, the AFP level drops rapidly in the maternal serum, but remains high in the newborn for about 3–4 weeks (fig. 3). The high AFP level in the newborn rat is associated with continued proliferation of hepatocytes in the liver until about 3 weeks after birth, when liver cell proliferation ceases. Then the AFP level declines rapidly [26].

Fig. 3. Changes in serum levels of AFP during normal development, after liver injury, during growth of a transplantable hepatoma and during chemical hepatocarcinogenesis. During pregnancy, the serum AFP of the fetus rises exponentially to reach levels 2 logs higher than in the maternal serum. The serum level remains elevated for about 3 weeks after birth and then rapidly falls to the adult normal level. The maternal serum AFP falls immediately after delivery. After liver injury, there is a short eleva-

tion of AFP associated with proliferation of liver cells. This is higher after chemical injury than after PH. During growth of a transplantable AFP-producing hepatoma, there is a steady elevation related to growth of the tumor. When the tumor is removed surgically, the AFP level drops, but rises again when there is growth of lung metastases. During chemical hepatocarcinogenesis, there may be a prolonged elevation of AFP, even with subcarcinogenic doses. Modified from Sell and Becker [21].

A possible function for AFP during development has intrigued investigators since the protein was discovered half a century ago [for reviews, see 27, 28]. Three major hypotheses have been tested. (1) AFP is immunosuppressive, serving to protect the fetus from immune rejection by the mother [29–31], (2) AFP carries vital fatty acid building blocks to the fetal neurons in the developing brain [32] and (3) AFP binds to estrogen and prevents masculinization of the developing female brain [33–35]. In regard to the first hypothesis, immunosuppression, we obtained mixed results [36, 37]. In most instances, AFP increased the immune responses; for example, AFP increased the induction of cytotoxic T cells by 9-fold in mice. It is of critical importance to include controls. Both albumin and AFP inhibited mitogen responses in vitro. In support of the second hypothesis is the fact that AFP protein is present in developing neurons [32, 38–40], but mRNA_{AFP} is not [41], suggesting that AFP could be a car-

rier protein to deliver building blocks required for normal brain development. Since it binds fatty acids required for myelination [32], AFP was proposed to be essential for normal myelination. This remained a viable hypothesis until the demonstration that AFP knockout mice, developed by Szpirer and coworkers [33–35], are born and develop normally; that finding essentially eliminated immunosuppression or a carrier function as AFP's role. However, adult female AFP knockout mice are infertile, due to an inability of the pituitary to produce gonadotropins [34]. This defeminization of the female brain in the AFP knockout mice can be blocked by administration of estrogen inhibitors (aromatase inhibitors). Thus, if neither AFP nor estrogen is present, defeminization of the female brain does not occur. Szpirer and coworkers concluded that AFP serves to sequester estrogen during development of the mouse brain, thus protecting the developing female mice from defeminization. However, the

Fig. 4. Production and distribution of AFP in the fetal-maternal unit. Fetal-maternal distribution of AFP (**a**) and in situ hybridization of cDNA for AFP to mRNA_{AFP} in yolk sac endoderm (**b**) and fetal hepatocytes (**c**) are shown. **a** Radiolabeled purified AFP was injected into various fetal and maternal fluid compartments and the presence of radioactivity in other fetal and maternal compartments after different times was determined. Modified from Sell and Skelly [22] and Sell and Alexander [24]. AFP synthesis was determined by incorporation of radiolabel arginine into cultures of tissues and the location of mRNA_{AFP} in fetal and maternal tissues was determined. AFP is synthesized in the fetal yolk sac and liver and rapidly enters fetal blood and amniotic fluid, and then the maternal blood. **b, c** The black color in **b** shows mRNA for AFP in yolk sac endoderm; in **c** in fetal hepatocytes (courtesy of Zoran Ilic).

Color version available online

Fig. 5. Aging changes in rat liver and yolk sac mRNA_{AFP} and mRNA_{albumin}. The number of molecules per cell of messenger RNA for AFP and albumin was determined in culture cells and compared to transplantable Morris hepatoma 7777 cells. mRNA_{AFP} is high in yolk sac and fetal liver until birth. There is no mRNA_{albumin} in the yolk sac, but the number of molecules increased from fetal day 16 until about 2 weeks of age when it reaches adult levels. mRNA_{AFP} falls rapidly after birth and reaches adult levels at 4 weeks of age. The mRNA_{AFP} is higher in hepatoma 7777 than in fetal hepatocytes, but the level of mRNA_{albumin} in hepatoma 7777 is lower than in normal adult hepatocytes. From Sell et al. [25].

rodent findings are not necessarily applicable to humans, as human AFP does not bind estrogen. Thus, although various functions have been postulated, the fascinating problem of why there is a specific serum protein that is associated with fetal life, conserved in so many species, remains to be determined convincingly for all species. The next topic of this paper will be the effect of liver injury on AFP production.

AFP and Liver Injury

Various cells in the hepatocyte lineage respond to injury or loss of liver tissue by proliferation. During this proliferation, AFP is produced and released into the circulation. The ability of mature hepatocytes to restore the lost liver cells by rapid proliferation following PH or carbon tetrachloride (CCl₄) injury led to the conclusion that the liver did not contain liver tissue-determined stem cells.

Partial Hepatectomy

The classic model of liver regeneration is the proliferation of mature hepatocytes following two thirds PH [42]. In this model, the lost liver tissue is restored by proliferation of mature hepatocytes in the remaining liver cords [43]. Hepatocyte proliferation occurs within the first 48 h after PH and is followed by an acute elevation of AFP for about 5 days [44]. During active proliferation of the hepatocytes, AFP can sometimes be detected in hepatocytes undergoing mitosis [45]. Thus, whereas AFP is clearly a marker for liver progenitor cells in the yolk sac and fetal liver, there is reexpression of this stem cell marker when adult liver cells proliferate. Repair of centrilobular necrosis of the liver after CCl₄ injury is also accomplished by proliferation of the remaining hepatocytes. In fact, Engelhardt et al. [46] reported that the surviving hepatocytes next to the necrotic central zone expressed AFP prior to division. Thus, liver stem cells are not involved in these repair reactions. However, a different result is obtained from other models of liver injury.

Chemical Injury

Treatment of the liver by toxic chemicals results in injury at different levels of the liver lobule [47, 48]. For example, CCl₄ produces centrilobular injury, galactosamine and lead nitrate act on midzone hepatocytes, allyl alcohol acts on periportal hepatocytes and a number of chemicals (α -naphthyl-isothiocyanate, 4,4'-diaminophenylmethane, furan) are toxic to bile duct cells [49]. Earlier studies using autoradiography led to the conclusion that

the precursors of bile duct cells and hepatocytes belong to nonoverlapping populations [50, 51]. It was stated that a duct cell or a liver cell 'reproduces only its own kind' [51]. On the other hand, our studies on liver injury indicated that there is a lineage of cells in the liver, and that cells at various differentiation levels in this lineage may respond to injury. Mature hepatocytes proliferate in response to PH and to CCl₄-induced centrilobular injury [42–46], midzonal hepatocytes respond to galactosamine and lead nitrate injury [52, 53], bipolar ductal cells respond when hepatocyte injury is accompanied by treatments that inhibit hepatocyte proliferation [54, 55] and ductular stem cells respond to duct injury induced by chemicals or bile duct ligation (fig. 6) [56, 57]. The presence of small periportal stem cells or hepatocyte progenitor cells is supported by the observation that liver injury by retrorsine is repaired by a population of small periductal hepatocyte-like cells even after the bile ducts have been destroyed by 4,4'-diaminodiphenylmethane [58].

The possible involvement of small periportal hepatocytes or putative periportal liver stem cells is best illustrated by the proliferative response of small intraportal oval cells to periportal necrosis induced by allyl alcohol in the rat [59–61] or by cocaine in the mouse [62]. These studies were originally designed to determine whether periportal liver cord cell injury would be repaired by proliferation of midzonal hepatocytes that replaced the damaged periportal cells, or by proliferation of putative liver stem cells or bipolar duct cells that then moved into the necrotic periportal zone [59]. The cellular response to periportal injury was a marked increase in small periportal cells, which filled the necrotic zone and then appeared to differentiate into hepatocytes [59–62, but see below for an alternative explanation]. The finding of a marked increase in small periportal cells after periportal injury raised the possibility that blood-borne stem cells entering the liver in the portal triad contribute to liver regeneration, perhaps through a small-cell intermediate.

Can Bone Marrow Cells Become Hepatocytes?

To determine whether blood-borne stem cells could contribute to liver regeneration, the contribution of bone marrow (BM)-derived cells to the liver was assessed after transplantation of donor-marked BM cells. For example, BM cells from male donors are transplanted into female recipients. In this case, the donor cells are detected by the presence of the Y chromosome [for reviews, see 63, 64]. Although there is considerable variation in results, in

Fig. 6. Cellular localization of AFP after various models of liver injury. **a** Immunofluorescence labeling of AFP in mitotic hepatocyte after PH [45]. **b** Immunofluorescence labeling of AFP in premitotic hepatocyte after CCl_4 induced central injury [46].

c Immunoperoxidase labeling of AFP in transitional oval cells after periportal injury induced by cocaine [59]. **d** Tritiated thymidine labeling of oval duct cells and periductular cells after CCl_4 injury and treatment with N-2-actylaminofluorene [55].

general, very few hepatocytes contain a donor marker (less than 1%). However, in mice with extensive and long-term loss of liver cells due to an inborn error of metabolism, over 50% of the liver cells are derived from BM cells after transplantation of donor cells without the metabolic defect [65, 66]. In this case, the liver is repopulated with liver cells that fuse with the BM-derived cells [64, 67, 68]. Because the fused cells are reprogrammed by the DNA of the BM-derived cells to express the gene that is defective in the recipient's liver, proliferation of these rescued cells leads to a selective survival advantage over the recipient's cells and restoration of the liver by fused cells. Much fewer donor-derived hepatocytes are seen in other models of

liver injury, such as in transgenic hepatitis B mice after treatment with retrorsine. However, it is not known how BM-derived cells become liver cells in models with less injury. Published studies on the ability of BM-derived cells to become liver progenitor cells (oval cells or small hepatocytes) have shown inconsistent results [69–77].

To determine whether BM-derived cells could be contributing to the small oval cells seen after chemically induced liver injury, we examined the livers of female mice transplanted with BM from male donors expressing the marker green fluorescent protein followed by injury at various levels of the liver lobule: CCl_4 , central injury; 3,5-diethoxycarbonyl-1,4-dihydrocollidine, ductal injury

Fig. 7. Effect of growth and amputation of transplanted Morris hepatoma 7777 on serum levels of AFP in Buffalo rats. Thirteen Buffalo rats were inoculated in the hind leg with 1×10^7 cells from transplantable Morris hepatoma 7777. The animals were then bled 2 times per week and the serum concentration of AFP measured by RIA. At 17 days the tumor-bearing legs of 8 of the transplanted mice were amputated. The shaded area shows the serum levels of the 5 control mice that were not treated by surgery. All control rats died by 40 days after tumor transplantation. The symbols show the levels of AFP in individual rats following amputation of the tumor. The serum levels fell rapidly after amputation, but elevations were then seen in 7 of 8 surgically treated rats. In each rat, elevation of AFP was associated with growth of metastases in the lung. The serum level of AFP of 1 of the 8 treated rats fell rapidly to below normal and remained there. This rat showed no evidence of regrowth or metastases of the tumor [81].

[78]; phenobarbital/cocaine, periportal injury [unpubl. data]. Hepatocytes proliferate after CCl_4 treatment, biliary ducts and cholangioles after 3,5-diethoxycarbonyl-1,4-dihydrocollidine and periportal oval cells after phenobarbital/cocaine. None of the proliferating liver lineage cells in the repair response to injury contained the donor marker. However, the livers of the recipient mice contained large numbers of donor-derived Kupffer, stellate and endothelial cells, as well as an infiltration of

small round cells (monocytes) derived from the BM. Months after repair of the injury, the number of hepatocytes containing green fluorescent protein or Y chromosome was not significantly different from the numbers in uninjured mice. Thus, it does not appear that BM-derived cells contribute to liver regeneration after injury through a putative stem cell or small hepatocyte intermediate [78]. Extensive analysis of the response to phenobarbital/cocaine has not been published, however, our results show that after this periportal injury there is a massive infiltration of BM-derived cells, but that these cells do not become liver cells. In contrast to our earlier interpretation that reconstitution of this injury was accomplished by periductular oval cells, it now appears that the early reconstituting cells are small hepatocytes [unpubl. data].

In conclusion, the general belief that the adult liver does not have stem cells is challenged by the findings on the expression of AFP during the cellular proliferative response to liver injury at various levels of the hepatic lobule. The liver gland consists of the same cellular lineage as in other tissues, namely, stem cells, transit-amplifying cells (ductule bipolar cells), ductal stem cells and mature hepatocytes. The unusual feature of the liver is not that it lacks stem cells (it does possess them), but rather that hepatocytes, the most differentiated cells of the liver, even those next to the central vein, are able to proliferate in response to injury. Somewhat unexpected was the finding that AFP is produced by all cells of the liver lineage when they proliferate, including the mature adult hepatocytes. This indicates that AFP is not only a developmental protein, but is also produced in adult liver in the proliferative response to injury. In the next section, we will see that AFP is also produced by HCCs, most prominently by proliferating cancer cells. Thus, AFP is not necessarily a marker for liver cancer stem cells because the transit-amplifying cells of the cancer also produce AFP.

AFP Production by HCCs

The maintenance of a library of transplantable rat HCCs induced by chemicals by Harold Morris in the 1960s [79] provided preclinical models with which the relationship of the serum concentrations of AFP to growth rate, histologic grade and chromosome composition of HCCs in tumor-bearing rats could be determined [80]. The author knows of no evidence that the tumor microenvironment contributes to the production of AFP by tumors, other than through support for the proliferation

of the cancer cells. Serum AFP levels in rats bearing fast-growing tumors, tumors with poor differentiation and tumors with aneuploidy were higher than levels in rats with more slowly growing, better-differentiated diploid tumors [80]. Clearly, the serum level of AFP correlates closely with the growth rate (number of dividing cells) and size of the tumor. Later clinical studies revealed similar correlations in human patients with HCC. Also, as in humans, serum AFP levels in rats bearing transplantable HCC could be used to follow the growth of HCC and response to therapy (fig. 7). For the preclinical study, we used a fast-growing, transplantable rat HCC that produced high levels of AFP (Morris hepatoma 7777). Following transplantation of hepatoma 7777 cells into the thigh of histocompatible Buffalo rats, the serum concentration of AFP rose exponentially as the tumor enlarged, until about 40 days, when the size of the tumor required that the animals be euthanized [81]. At this time point the serum concentration ranged between 7,000 and 10,000 $\mu\text{g/ml}$. The kinetics of the elevation of serum AFP paralleled the growth of the tumor. If the transplanted tumors were removed surgically at 17 days, the serum AFP levels fell, with a half-life of about 24 h. However, rapid elevations occurred with growth of metastatic lesions, mainly in the lung [81]. In another experiment, we found that irradiation of the lung at the time of surgical removal of the tumor could delay or prevent growth of pulmonary metastases. The effect of the irradiation on tumor growth was reflected by serum AFP levels [82]. This preclinical model proved to be a good one for the determination of how to use AFP in the diagnosis and management of human patients with AFP-producing tumors.

Further characterization of the cellular composition and biological behavior of Morris hepatomas in the 1960s revealed that these cancers contained cells with stem cell-like characteristics as recently publicized for other cancers [83, 84]. Notable among these characteristics was that cancer stem cells are able to grow *in vitro* (usually on soft agar), are able to initiate tumor growth upon transplantation (tumor-initiating cells) and can resist therapy. The fact that cells from these HCCs could be cultured *in vitro* argues for the presence of cells with stem-like properties (that is, immortality) in the hepatomas [85]. Transplantation of the Morris hepatomas revealed heterogeneity in growth properties. Some of the Morris hepatomas could be transplanted by means of just a few cells and grew very quickly, whereas others could only be transplanted by means of large numbers of cells and grew very slowly [86, 87]. These findings demonstrated the second property of cancer stem cells noted above, that is, tumor

initiation. Finally, extensive studies on the response to irradiation treatment by William Looney [88] demonstrated that after high-dose radiation, the tumors were able to regrow, indicating the presence of a therapy-resistant cancer stem cell. Thus, these studies published in the 1960s and 1970s demonstrated that Morris hepatomas contained cancer stem cells (see below for more recent studies on cancer stem cells in human hepatomas).

The expression of fetus-associated proteins by Morris hepatomas was interpreted by Van Rensselaer Potter to mean that these hepatomas arose by processes related to normal embryogenesis, that is 'oncology is blocked ontogeny' [89–91]. Morris HCCs expressed variable levels of adult and fetal liver enzymes [92–95], secreted variable levels of AFP [80] and displayed extents of hepatocellular differentiation ranging from well differentiated ('minimal deviation hepatomas') to poorly differentiated ('maximally deviated HCC') [96]. Potter suggested that the expression of fetal liver cell markers in HCCs was not due to dedifferentiation, but rather to a block in the maturation of the immature liver cells that gave rise to the cancer. This conception [89] antedated the findings on the production of AFP during chemical hepatocarcinogenesis, which will be covered in the next section of this paper.

Because of the potential for the clinical application of AFP to the diagnosis and monitoring therapy of cancers associated with production of AFP, the author, 2 postdoctoral fellows and a laboratory technician at the University of Pittsburgh developed a test kit (Feto-Tect) for the detection of human AFP that became used throughout the world from 1969 thorough 1974 [97]. The test was based on a simple double diffusion in agar plate, and could be applied in the field without requirement of a laboratory (fig. 8). It was especially useful in high HCC incidence areas of the world, such as South Africa and China. However, the Feto-Tect test was removed from interstate commerce in 1974 by the United States Food and Drug Administration because overinterpretation of CEA measurements had led to unnecessary surgery for colon cancer [97]. Even though assays for AFP were not a problem, they were linked to CEA as oncodevelopmental markers and also removed. Even when the test for CEA was reinstated, that for AFP was not. We were unable to obtain an explanation. When AFP testing finally gained approval, the tests for certification were so expensive to conduct that only large companies could afford to obtain the data required. Now AFP testing for HCC is a standard approved procedure.

In conclusion, AFP production by HCC is related to growth rate, size and chromosome composition of the

Fig. 8. Feto-Tect double diffusion in agar for detection of human AFP. The test kit included a positive control AFP serum (left well), a negative control serum (bottom well) and anti-AFP (right well). The patient's serum to be tested was placed in the top well. The reaction of the positive control with the anti-AFP resulted in a precipitin-in-agar line that ran between the top and bottom wells. If the patient's serum contained AFP, the line would deviate from the top well. The sensitivity of the test was about 100 ng/ml. This test kit was sold internationally by Fernwood Laboratory (Pittsburgh, Pa., USA) from 1969 until 1974. In 1974 the test was taken off the market by the United States Food and Drug Administration because of its association with CEA as an oncofetal antigen. The company was formed by 2 fellows, Richard Baney and James Storey, and a technician, Art Park, in the author's laboratory in 1968 [97].

tumor. Slowly growing, well-differentiated HCC generally are not associated with elevated serum AFP, whereas fast-growing, poorly differentiated HCCs produce high serum AFP concentrations. However, significant exceptions are found: some fast-growing, near-diploid HCCs do not cause elevations, whereas some slowly growing euploid HCCs do. The production of AFP by HCC identifies the protein as an 'onco' protein and represents the reexpression of a developmental product during oncogenesis. Characterization of the growth properties, transplantability and response to therapy of the experimental Morris rat hepatomas supports the conclusion that these tumors contain cancer stem cells. The next section reviews the data on the production of AFP during chemical hepatocarcinogenesis, that led to the hypothesis that HCCs arise from stem cells [98].

AFP and Chemical Hepatocarcinogenesis

Dedifferentiation: Foci to Nodules to Cancer

Detailed histologic and histochemical analyses by many investigators studying chemical hepatocarcino-

genesis led to the hypothesis that liver cancer arises from dedifferentiation of hepatocytes. For a detailed review of this subject, with more complete references than listed in this paper, the reader is referred to a recent review by the author [98]. The induction of human liver cancer by chemicals began to be seen in Japan in the 1930s and in other places in the 1940s due to development of the chemical dye industry. Pathologists clearly described the major histologic findings in the liver that preceded the appearance of liver cancer in experimental models of chemical hepatocarcinogenesis [99–102]. The 2 major observations were the proliferation of small round cells and the development of nodules in the liver that came to be called neoplastic nodules. After World War II, hepatocarcinogenesis became a major area of investigation in the United States, as exemplified by the extensive work of Emmanuel Farber [103, 104] and Henry Pitot [105], as well as in Germany [106–110]. The extensive proliferation of small round cells, designated 'oval cells' by Farber [9, 10, 103, 104] and the development of foci of altered staining of hepatocytes and increasing nodularity in the liver were described. However, the striking sequence of foci → nodule → HCC was interpreted to mean that HCC developed by dedifferentiation of hepatocytes [98, 110]. This interpretation became the accepted dogma for the cellular origin of HCC.

AFP Production during Chemical Hepatocarcinogenesis

Analysis of the production of AFP during chemical hepatocarcinogenesis led to a major change in the paradigm for the cellular origin of cancer. As noted above, the author joined the department of Emmanuel Farber in 1965, at the height of the investigation of the biochemical and cellular changes in the liver during chemical hepatocarcinogenesis. It was generally thought that the determination of the biochemical changes taking place during development of neoplastic nodules would reveal how and why cells become cancerous [98–110]. With the discovery in 1963 that AFP was associated with cancer [4], it was postulated that the decipherment of where AFP was produced during the development of HCC, would further our knowledge of the carcinogenic process. After the sensitive RIA for AFP was developed [20], we undertook an extensive study of the kinetics of the elevation of serum AFP during the hepatocarcinogenic process [for review, see 21]. Unexpectedly, we found that the kinetics of elevation varied, depending upon which of the chemical carcinogenic models was used [21, 111]; this finding forced the realization that the cellular localization of AFP is reg-

imen dependent [47]. The regimen specificity of AFP localization will be illustrated for 4 regimens: cyclic N-2 fluorenylacetamide (AAF), choline deficiency AAF (CD-AAF), the Solt-Farber model (SF) and diethylnitrosamine (DEN).

Cyclic AAF

The cyclic AAF regimen of George Teebor and Fred Becker [112] was chosen first for study because of the consistent progression of liver lesions from foci to nodules to cancer. In this model, AAF is fed for 3-week-on, 1-week-off cycles. Since the AAF is in itself toxic if fed continuously, the week-off periods allow the rats to recover. At the end of the first cycle, small cellular foci of 8–10 altered cells are seen. If the feeding is discontinued, the foci disappear. At the end of the second cycle, small nodules are present in the liver cords. Again, if feeding is discontinued, the nodules disappear. After the third cycle, larger nodules are grossly visible. Again, if feeding is discontinued, the nodules disappear. After the fourth cycle, the nodules are much larger and distort the liver grossly. If feeding AAF is discontinued at this point, liver cancer will develop about 21 weeks after the fourth cycle. After the fourth cycle, hundreds of nodules of different sizes may be evident in the liver. Most of these regress, but a few do not (persistent nodules); of the latter, a small number were believed to become HCC. When the serum AFP levels were measured by RIA, in contrast to what was expected, there was an immediate elevation during the first cycle [111]. The serum AFP levels fell during the third and fourth cycles when the nodules were the predominant feature, and then rose later when HCCs developed. When the liver was examined histologically, the early AFP rise correlated with a marked increase in the number of small oval cells in between the nodules [113]. Thus, the elevation of serum AFP correlated not with the development of nodules, but rather with the presence of oval cells. Immunofluorescent cellular localization of AFP revealed that the AFP was present in the oval cells and not in the foci or nodules. This unexpected localization indicated that the origin of HCC is not through the foci-to-nodule pathway, but instead through the small, AFP-positive oval cells. Since the HCCs that develop in this model produce AFP, it is more likely that the HCCs arise from oval cells than from hepatocytes. Based on these data and the results of some of the injury experiments described above, we postulated that tissue-determined stem cells exist in the liver, either in the terminal ducts or the intraportal zone, and that these stem cells proliferated in response to carcinogens and gave rise to HCC [25, 114].

Choline Deficiency AAF

To determine the origin of the oval cells, we chose the CD-AAF model of Shinozuka and Lombardi. In this model, there is very rapid appearance of oval cells within days of the start of the regimen [115, 116]. The rapid proliferation of the oval cells allowed us to label the proliferating cells by pulse labeling using tritiated thymidine [117, 118]. Light microscopy revealed that within 1–2 days, there is an increase in labeled small round cells next to the bile ducts in the intraportal zone, and then an increase in labeled cells within the bile ducts. During the next 2–3 weeks, labeled oval cells extend across the liver lobule to the central vein [118]. By electron microscopy, the first identifiable labeled cells were cells containing very few organelles, which were located in the intraportal tissue outside the basement membrane of the bile ducts [118]. The results of these experiments confirmed our previous speculation that putative liver stem cells are located in the intraportal zone as well as within the bile ducts [25, 114].

SF Model

The complex SF regimen was designed to activate proliferation of hepatocytes initiated following exposure to carcinogen (DEN). The supposition is that when proliferation of noninitiated hepatocytes is inhibited (AAF treatment), there will be selective stimulation of proliferation of the initiated hepatocytes following PH [119]. Thus, the regimen consists of administration of DEN (initiation), followed 2 weeks later by a 2-week treatment with AAF (inhibits hepatocyte proliferation), with a PH done during the middle of the AAF exposure (stimulates proliferation of initiated cells). Using this model, we found a rapid increase in AFP occurring shortly after the PH [120]. The level of AFP increased until about 2 months after PH and then dropped to essentially normal. Another elevation of AFP occurred after 10 months when HCC began to form. However, in contrast to the cyclic AAF model, the AFP in this model was not found in periportal cells, but rather in newly formed duct cells [120]. Thus, in this model, the cells giving rise to HCC appear to be the bipolar bile ductular progenitor cells.

Diethylnitrosamine

After continuous exposure of rats to DEN, serum AFP levels do not rise until 6–8 weeks after exposure, but then steadily increase as HCCs grow [120]. Cellular localization is first seen not in oval cells or duct cells, but in small atypical foci of hepatocytes. These foci enlarge to form microcarcinomas and later HCC. Thus, in this model, HCCs appear to arise directly from hepatocytes [120].

Fig. 9. Cellular origin of proliferating liver cells during various models of chemical hepatocarcinogenesis in the rat. The top of the figure shows the location of the cellular reaction to cyclic AAF. **a** AFP-positive intrahepatic oval cells by immunofluorescence af-

ter cyclic AFP [113]. **b** New duct cells staining for OV-6, a monoclonal antibody to oval cells, during the cellular reaction to the SF model of hepatocarcinogenesis [121]. **c** AFP-positive microcarcinomas by immunoperoxidase after DEN exposure [120].

Summary

A summary of the cellular changes in the liver arising from various carcinogen regimens is shown in figure 9. Depending on the regimen, HCC can arise from intra-portal nonductal stem cells, ductal bipolar transit-amplifying progenitor cells or hepatocytes. This variability indicates that HCC can arise from a number of cell types in the hepatocyte lineage: stem cells, transit-amplifying cells and mature hepatocytes [122]. If cancer is a problem of maturation arrest, we would expect that the differentiation phenotype for HCC arising from stem cells would differ from that of HCC arising from ductal progenitor cells or from mature hepatocytes. However, all these protocols result in HCC. The missing link in the cellular hierarchy of the liver and liver cancer appears to be the liver cancer of early childhood, hepatoblastoma [123].

Hepatoblastomas. Hepatoblastomas are tumors of childhood with approximately two thirds occurring within the first 2 years of life, and 90% within the first 5 years of life [123]. Hepatoblastomas are made up of cells at various stages of differentiation, from small round embryonal cells to fetal-like cells that form primitive liver cords [124, 125]. The small cells grow in sheets and are

similar to neuroblastoma and other primitive tumors of childhood. This embryonal phenotype suggests that there is a loss of potential of liver-determined stem cells with aging, such that HCCs arising in the livers of adults are the more highly differentiated HCCs, whereas those arising in the livers of young children reflect the less differentiated stage of the liver-determined stem cell [98]. A relationship of the cellular origin of liver cancer to the stage of maturation arrest of liver lineage cells is shown in figure 10.

From this model, we conclude that HCCs arise from maturation arrest of differentiation and not from dedifferentiation [47, 114, 120, 122]. Thus, even though some HCCs arise from hepatocytes, liver cancer is not an exception to the general rule that cancers arise from stem cells, since hepatocytes represent one stage of liver cell differentiation. Mature hepatocytes are not terminally differentiated and can be activated to proliferate. The conclusion that liver cancer – one of the least likely cancers to arise from stem cells – actually does so, led to a general hypothesis that essentially all cancers arise from maturation arrest of tissue-determined stem cells [126].

Fig. 10. Diagram of cellular lineage of hepatocarcinogenesis. Cancers of the liver may arise from fetal hepatocytes (hepatoblastomas) or from adult cells at different stages of the hepatocyte lineage, stem cells, bipolar ductal progenitor cells or mature hepatocytes. This model differs from most tissue lineages because even the most mature cells in the hepatocyte lineage, the central hepatocytes, may proliferate in response to injury. This implies that there are no terminally differentiated cells in the liver, and thus HCCs may arise from any cell in the liver lineage. The lineage of teratocarcinomas is illustrated in figure 11 [98].

Is There a Carcinogenic Role for AFP? The association of AFP production by premalignant cells and early carcinomas suggested a possible role of AFP in tumorigenesis or tumor progression [27]. There is no evidence known to this author that the presence of production of AFP has a role in induction of cancer, but appears to be reexpression of a developmental protein. However, it is possible that AFP contributes to controlling progression. For example, some tumors have a receptor for AFP and the serum level of this receptor may be more accurate than other tumor markers [127, Moro et al., pers. commun.]. Reaction of AFP with these receptors may affect nuclear transcription, apoptosis or signal transduction, but these activities are demonstrated in vitro and as yet no treatment applications have even approached study [27]. On the other hand, AFP, especially of murine species, is known to bind estrogen, and AFP [128, 129] or peptides derived from AFP [130] may inhibit growth of estrogen-dependent tumors. Again, since human AFP binds estrogen poorly, it is unlikely that human AFP has this effect. However, the possibility of treating estrogen-dependent tumors with AFP peptides has been proposed [129].

The Stem Cell Theory of the Origin of Cancer

The theory that cancers arise from stem cells was the first rational theory of cancer. It was first propounded by Joseph Claude Anselme Recamier in 1829 [131], and later by Robert Remark [132]. Prior to this theory, cancers had been considered to arise through an imbalance of black bile, an extension of the humoral theory of disease. A variation of the humoral theory was favored by Sir James Paget, and even Rudolph Virchow, the father of pathology, believed that cancers arose from connective tissue during chronic inflammation [133]. The concept that cancers arise from stem cells became known as the embryonal rest theory of cancer [134, 135]. This theory postulated that cancers arose in adult tissues from small collections of embryonal cells that did not differentiate. Although this idea became popular, other ideas gradually superseded it. For example, Hugo Rippert thought that cancers came from displaced tissue that lost the restraining influence of surrounding tissue, and Amedee Borrel favored parasitic infection as a cause. By 1914, Theodor Boveri had found chromosomal abnormalities in cancers, and he concluded that cancers arose from mature cells that mutated. Such findings led William Seaman Bainbridge, in his monumental book *The Cancer Problem*, to reach the following conclusion: 'The congenital or embryonic theory of the origin of cancer has received no support whatever from the experimental and comparative investigations of recent times' [136]. However, studies on teratocarcinoma pointed the way back to the stem cell theory of the origin of cancer and cancer stem cells.

Teratocarcinoma

Rudolf Virchow, although noting the resemblance between developing embryonic tissues and the tissues that made up teratocarcinomas, concluded that cancers arose from inflammatory granulation tissue [133]. The contribution of the study of teratocarcinoma to reconsideration of the theory of the stem cell origin of cancer took place after World War II. Teratocarcinomas are cancers arising usually in the testes or ovaries, which contain a mixture of normal, mature well-differentiated cells representing essentially every mature tissue of the body. Thus, most cells of a teratocarcinoma are benign mature cells. The malignant stem cells of a teratocarcinoma form a structure that resembles an early embryo (embryoid body) [137]. Only the cells in the embryoid body are actively proliferating and only they give rise to the other differentiated tissues

in the tumor, including brain, muscle, bone, BM, eyes, secretory glands and skin. Teratocarcinomas usually also contain yolk sac elements that produce AFP, and choriocarcinoma elements that produce human chorionic gonadotropin HCG. These markers can be used for diagnosis and for tracking the results of therapy of those teratocarcinomas which contain yolk sac or chorionic elements [138–140]. In 1954, LeRoy Stevens, a veteran fighter pilot from World War II, published his studies on the production of transplantable teratocarcinomas through injection of the normal male germinal cells from an SJ/129 mouse, that has a high rate of spontaneously appearing teratocarcinoma, into the normal testes of a 129 mouse [141]. The transplantation of these cells resulted in growth of teratocarcinomas arising from the normal germinal cells, proving that cancers can arise from normal germinal stem cells placed into an abnormal tissue environment [142, 143]. The concept that environmental signals can be critical in the development of cancer was predicted by Cohnheim in 1875 [135], and restated by Rippert in 1911 [144]. Incidentally, transplantation of extraembryonic yolk sac cells of 9-day-old embryos to the rat kidney capsule results in growth of yolk sac tumors that produce AFP, whereas transplantation of the embryonic portion of the embryo gives rise to teratomas that do not produce AFP [145].

Extensive study of the growth and differentiation properties of experimental teratocarcinomas by Barry Pierce and coworkers established that many of the progeny of the malignant cells of teratocarcinomas differentiate into mature benign tissue [8, 146]. This was also shown to be the case for other cancers, specifically squamous cell carcinoma [147]. The difference between cancer and normal tissue renewal is that in normal tissue renewal, the number of cells that are proliferating is essentially equal to the number of cells terminally differentiating (undergoing apoptosis), whereas in cancer the number of cells that are proliferating (transit-amplifying cells) is greater than the number of cells that are entering terminal differentiation, because of maturation arrest of the cancer cells in the transit-amplifying population [126].

The most impressive demonstration of the role of the environment, in inducing differentiation of cancer stem cells, are the blastocyst transplantation experiments. Using the method developed by Brinster [148] for injection of cells into developing blastocysts, Mintz and Illmensee [149] and Papaioannou et al. [150] reported in 1975 that teratocarcinoma stem cells could be controlled by the environment of the developing blastocyst. When teratocarcinoma cells were injected into the inner cell mass of the developing blastocyst and the embryos were allowed to

Fig. 11. Diagram of cellular lineage of germinal cell tumors. The lineage of germinal cell cancers begins with the totipotent neoplastic germinal cells and includes embryonal carcinoma, seminoma and spermatocytic seminoma. Embryonal carcinoma cells may give rise to choriocarcinomas, yolk sac carcinomas, teratomas and mixed cell tumors.

mature, the carcinoma-derived cells differentiated into fully functioning mature tissue in chimeras made up of mixtures of carcinoma- and blastocyst-derived cells. Pierce et al. [151] then demonstrated that the germinal layers of the blastocysts determine the types of cells into which the transplanted embryonal carcinoma cells develop. Thus, the actual carcinoma stem cells undergo complete differentiation to benign cells, leading to the conclusion that ‘tumors are caricatures of normal tissue renewal’ [152]. A diagram illustrating the differentiation pathway of cancers arising from germinal cells, and the possible stages of maturation arrests, is shown in figure 11. Embryonal carcinomas can be treated with agents such as retinoic acid (vitamin A), which induces differentiation of the malignant cells to benign cells [153]. However, human teratocarcinomas are more effectively treated by surgery and chemotherapy. The ability to induce differentiation in teratocarcinomas from malignant to benign cells establishes the precedent for differentiation therapy of cancer [154–156].

Differentiation Therapy of Leukemias

The success of differentiation therapy is arguably best exemplified by the treatment of myeloid leukemias [157, 158], where appropriate differentiation therapy forces

differentiation of malignant cells. Examples of the various forms of myeloid leukemia are chronic myeloid, subacute promyeloid and acute myeloid (blastic). Each of these is caused by gene translocations that result in constitutive activation of signaling cascades or blocking of apoptotic pathways. Differentiation therapy is directed toward disruption of these signaling pathways, or activation of apoptotic pathways. For example, Gleevec binds to and inactivates the bcr/abl tyrosine kinase formed in chronic myeloid leukemia. This inactivation blocks the signaling pathway and allows the cells to differentiate [159]. In subacute promyeloid leukemia, fusion of the promyeloid leukemia region (PML) with the retinoic acid receptor (RAR α) gene results in inhibition of the formation of cytoplasmic granules required for differentiation [160, 161]. In this way, the maturation of the leukemic cells is blocked at the promyelocyte stage. Treatment with retinoic acid induces breakdown of the PML/RAR α gene fusion product and allows the promyelocytic leukemia cells to differentiate. In acute myeloblastic leukemias, there is usually both activation of signaling pathways for proliferation and inhibition of an apoptotic pathway [162]. These provide a one-two punch, so that the number of proliferating cells is increased and the cells produced do not die. Treatments with agents that inhibit the activation pathway and activate apoptosis in acute myeloblastic leukemia are now being tested clinically [163, 164].

Cancer Stem Cells

As discussed above, there are 2 components to cancer stem cell models: cancers arise from tissue stem cells and cancers contain stem cells. The preceding sections of this paper have largely covered the hypothesis that cancers arise from stem cells. In the last section of this paper, the concept of cancers containing stem cells and therapy directed to these cancer stem cells will be presented. First, there are 3 major biological properties of cancer stem cells: the ability to grow in soft agar, the capacity to transplant the tumor (tumor initiating cells) and the ability to resist radio- and chemotherapy.

Growth in Agar

Growth of cancer cells on soft agar was first described for HeLa cells in 1955 [165] and later for cells from primary human tumors [166]. Salmon [167] found that 1:1,000 to 1:100,000 cells from a primary human adenocarcinoma would form colonies in soft agar (called tumor colony-forming units) and proposed to use these cultured

cells to study the effects of various drug treatments. This range of proportions of tumor colony-forming units is similar to the proportions recently found for the tumor-initiating cells in acute myelogenous leukemia (see below).

Tumor Transplantation and Tumor-Initiating Cells

The second property proposed for a cancer stem cell is that it can initiate tumor growth when transplanted to syngeneic or immunocompromised recipients [168–173, for review, see 83]. The frequency of tumor-initiating cells was later found to be of the same order of magnitude as the frequency of cells that survive after chemo- or radiotherapy and grow in soft agar. The evidence for transplantable liver cancer stem cells was discussed above under the properties of Morris hepatomas. Briefly, some of the Morris hepatomas could be transplanted by means of just a few cells and grew very quickly, whereas others could only be transplanted by means of large numbers of cells and grew very slowly. These observations again suggest cellular heterogeneity in hepatomas, but neither systematic dilution nor fluctuation analysis experiments were performed. Consequently, there is as yet no clear identification, in this model system, of the percentage of cells with tumor-initiating properties for HCC.

With the relatively recent recognition that the cells with stem cell properties in a cancer might be identified by ‘stem cell’ markers, a number of attempts to identify such cells in HCC have been reported. By gene expression analysis, Lee et al. [174] were able to identify at least 3 types of human liver cancers and poor prognosis is associated with HCC with less differentiated expression. Specific markers that appear to identify stem-like cells in human HCC include CD133 [175–177], CD90 [178, 179], ABCG2 [180], epithelial cell adhesion molecule (EpCAM) [181] and Met [182]. CD133 and CD90 expression are associated with fetal liver cell marker expression, tumor initiation, culture in vitro and chemoresistance [175–179], properties attributed to cancer stem cells. Further study of the properties of these cells may lead to modalities of therapy for HCC directed at the cancer stem cells (see below).

Resistance to Radio- and Chemotherapy

The transplantable tumor cells that are resistant to therapy may differ from other cells in the cancer (cancer stem cells as distinct from the cancer transit-amplifying cells), or transplantable cells may merely be quiescent cells that respond poorly to therapy and survive the challenges of transplantability. These alternatives were pre-

sented in commentaries in 1994. Trott [183] supported the concept that the cells from transplantable mouse tumors meet the criteria of a tumor stem cell, that is, 're-growth of the tumour preceded by clonal expansion from a single cell with unlimited proliferative potential'. He concluded that tumors contain the same populations of cells as normal tissue, consistent with the proposal of Pierce et al. [8], derived from studies on teratocarcinoma. On the other hand, in a companion paper, Denekamp [184], argued that the putative cancer stem cells might be considered the least differentiated cells of a cancer cell population, functionally and kinetically different from the remaining mass of tumor cells, but not necessarily stem cells.

Cancer Stem Cells and Therapy

The recognition that cancers contain the same lineages of cells as normal tissues, that is, stem cells, transit-amplifying cells and differentiated cells [126, 152], suggests that a cure for cancer should be directed against the cancer stem cells. Therefore, even if all proliferating transit-amplifying tumor cells were killed therapeutically, tumorous tissues would reemerge from therapy-resistant cancer stem cells. In support of this possibility, highly tumorigenic subpopulations of putative cancer-initiating 'stem' cells derived from human glioblastomas have been found to display resistance to radiation because of increased protection against DNA damage [185]. Provocative qualitative and quantitative theoretical discussions of immortal DNA strands, an obligate property of normal stem cells, and certain predicted DNA repair deficiencies in somatic cancer cells have also been reported [186, 187]. However, little is known about the role of putative liver cancer stem cells in resistance to therapy, although it may be presumed that regrowth of HCCs after effective treatment may be mediated by putative liver cancer stem cells. Although this cannot be proven, it is the most likely explanation.

The models of therapy now in use are directed against the transit-amplifying cells. As depicted in figure 12, radiation therapy, chemotherapy and antiangiogenic therapy inhibit proliferation of actively dividing cells, whereas differentiation therapy inactivates signals that cause maturation arrest, thereby allowing terminal differentiation of transit-amplifying cells [154–158]. Even if these approaches are successful, the cancer stem cell remains and the tumor retains the potential to regrow from the cancer stem cells.

Fig. 12. Levels of therapy for cancer. Radiation therapy and chemotherapy kill proliferating transit-amplifying cells of a cancer. Antiangiogenic therapy inhibits the blood supply to the proliferating cells. Differentiation therapy reverses maturation arrest and allows proliferating cancer cells to terminally differentiate. Even if these approaches are successful, cancers may regrow from cancer stem cells that are not affected by these therapies. It is hypothesized that cancer stem cell inhibition therapy would block the proliferation of cancer stem cells and prevent regrowth [188].

New experimental therapy approaches are directed toward signaling pathways active in maintaining cancer stem cells through use of inhibitory RNA or small blocking molecules. Some of these blocking agents are listed in a previous publication by the author [156, table 1]. If stem cell therapy is to be applied successfully, then the regrowth of the cancer after successful treatment of the cancer transit-amplifying cells can be prevented.

References

- 1 Bergstrand CF, Czar B: Demonstration of a new protein fraction in serum from the human fetus. *Scand J Clin Lab Invest* 1956;8: 174.
- 2 De Murali G, Roulet DLA: Etude immunologique des protéines sériques fœtales humaines. *Helv Paediat Acta* 1961;16:517–533.
- 3 Masopust J: Development of serum protein spectrum during childhood. *Rev Czech Med* 1962;8:214–225.

- 4 Abelev GI, Perova SD, Khramkova NI, Postnikova AS, Irlin IS: Production of embryonal α -globulin by transplantable mouse hematomas. *Transplantation* 1963;1:174–180.
- 5 Tatarinov YS: Presence of embryonal α -globulin in the serum of patients with primary hepatocellular carcinomas. *Vopr Med Khim* 1964;10:90–91.
- 6 Gold P, Freedman SL: Specific carcinoembryonic antigens of the human digestive system. *J Exp Med* 1965;122:467–481.
- 7 Fishman WH, Sell S: *Onco-Developmental Gene Expression*. New York, Academic Press, 1976, pp 1–788.
- 8 Pierce GB, Shikes R, Fink LM: *Cancer: A Problem of Developmental Biology*. Englewood Cliffs, Prentice Hall, 1978, pp 1–242.
- 9 Farber E: Ethionine carcinogenesis. *Adv Cancer Res* 1963;7:383–474.
- 10 Farber E, Cameron R: The sequential analysis of liver cancer induction. *Adv Cancer Res* 1979;31:125–226.
- 11 Farr RSA: Quantitative Immunochemical measure of the primary interaction between I*BSA and antibody. *J Infect Dis* 1958;103:237–262.
- 12 Yalow RS, Berson SA: Immunoassay of endogenous insulin in man. *J Clin Invest* 1960;39:1157–1175.
- 13 Sell S: Radioimmunoassay of rat α 1-fetoprotein. *Cancer Res* 1973;33:1010–1015.
- 14 Gitlin D, Boesman M: Sites of α -fetoprotein synthesis in the human and in the rat. *J Clin Invest* 1967;46:1010–1016.
- 15 Sell S, Jalowsky I, Bellone C, Wepsic HT: Isolation and characterization of rat α 1-fetoprotein. *Cancer Res* 1972;32:1184–1189.
- 16 Ruoslahti D, Seppala M: Studies on carcino-fetal proteins III: development of a radioimmunoassay for α -fetoprotein – demonstration of α -fetoprotein in healthy human adults. *Int J Cancer* 1971;8:374–383.
- 17 Purves LR, Purves M: Serum AFP VI: the radioimmunoassay evidence for the presence of AFP in the serum of normal people and during pregnancy. *S Afr Med J* 1972;46:1290–1298.
- 18 Oakes DD, Shuster J, Gold P: Radioimmunoassay for α 1-fetoprotein in the serum of rats. *Cancer Res* 1972;32:2753–2760.
- 19 Hirai H, Nishi S, Watabe H: Radioimmunoassay for α -fetoprotein; in Peeters H (ed): *Protides of the Biological Fluids*. Oxford, Pergamon Press, 1973, pp 579–587.
- 20 Sell S, Gord D: Refinement of radioimmunoassay for detection of 1 ng rat α -1 fetoprotein. *Immunochemistry* 1973;10:439–442.
- 21 Sell S, Becker FF: α -Fetoprotein. *J Natl Cancer Inst* 1978;60:19–26.
- 22 Sell S, Skelly H: Tissue sites of α 1-fetoprotein synthesis by the rat during pregnancy and hepatoma growth. *J Natl Cancer Inst* 1976;56:645–648.
- 23 Sala-Trepat JM, Dever J, Sargent TD, Thomas K, Sell S, Bonner J: Changes in expression of albumin and α -fetoprotein genes during rat liver development and neoplasia. *Biochemistry* 1979;18:2167–2178.
- 24 Sell S, Alexander D: Rat α -1-fetoprotein. V. Catabolism and fetal-maternal distribution. *J Nat Cancer Inst* 1974;52:1483–1489.
- 25 Sell S, Sala-Trepat J, Sargent T, Thomas K, Nahon J-L, Goodman T, Bonner J: Molecular mechanisms of control of albumin and α -fetoprotein production: a system to study the early effects of chemical hepatocarcinogens. *Cell Biol Int Rep* 1980;4:235–254.
- 26 Sell S, Nichols M, Becker FF, Leffert JL: Hepatocyte proliferation and α 1-fetoprotein in pregnant, neonatal and partially hepatectomized rats. *Cancer Res* 1974;34:865–871.
- 27 Mizejewski GJ: α -Fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. *Exp Biol Med* 2001;226:377–408.
- 28 Mizejewski GJ: Biological roles of α -fetoprotein during pregnancy and perinatal development. *Exp Biol Med* 2004;229:439–463.
- 29 Parmely MJ, Thompson JS: Inhibition of rat lymphocyte cultures by serum fractions rich in α -fetoprotein; in Masseyeff R (ed): α -Fetoprotein. Paris, Inserm, 1974, p 467.
- 30 Murgita RA, Tomasi TB: Suppression of the immune response by α -fetoprotein. I the effect of mouse α -fetoprotein on the primary and secondary antibody response. *J Exp Med* 1975;141:269–286.
- 31 Murgita RA, Tomasi TB: Suppression of the immune response by α -fetoprotein II. The effect of mouse α -fetoprotein on mixed lymphocyte reactivity and mitogen induced lymphocyte transformation. *J Exp Med* 1975;141:440–452.
- 32 Uriel J, Trojan J, Moro R, Pineiro A: Intracellular uptake of α -fetoprotein: a marker of neuronal differentiation. *Ann NY Acad Sci* 1983;417:321–329.
- 33 Gabant P, Forrester L, Nichols J, Van Reeth T, De Mees C, Pajack B, Watt A, Smitz J, Alexandre H, Szpirer C, Szpirer J: α -Fetoprotein, the major fetal serum protein, is not essential for embryonic development but is required for female fertility. *Proc Natl Acad Sci USA* 2002;99:12865–12890.
- 34 DeMeas C, Laes J-F, Bakker J, Smitz J, Hennuy B, Van Vorren P, Gabant P, Szpirer J, Szpirer C: α -Fetoprotein controls female fertility and prenatal development of the gonadotropin-releasing hormone pathway through an antiestrogenic action. *Mol Cell Biol* 2006;26:2012–2018.
- 35 Bakker J, DeMeas C, Souhard Q, Balthazart J, Gabant P, Szpirer J, Szpirer C: α -Fetoprotein protects the developing female mouse brain from masculinization and defeminization by estrogens. *Nat Neurosci* 2006;9:220–226.
- 36 Sheppard HW, Sell S, Threfts P, Bahu R: Effects of α -fetoprotein on murine immune responses. I. Studies on mice. *J Immunol* 1977;119:91–97.
- 37 Sheppard HW, Sell S, Threfts P, Bahu R: Effects of α -fetoprotein on murine immune responses. II. Studies on rats. *J Immunol* 1977;119:98–103.
- 38 Attardi B, Ruoslahti E: Foetoneonatal oestradiol-binding protein in mouse brain cytosol is α -fetoprotein. *Nature* 1976;263:685–687.
- 39 Benno RW, Williams TH: Evidence for intracellular localization of α -fetoprotein in the developing rat brain. *Brain Res* 1978;142:182–186.
- 40 Trojan J, Uriel J: Intracellular localization of α -fetoprotein and serum albumin in the central nervous system of the developing rat. *CR Seances Acad Sci* 1979;289:1157–1160.
- 41 Sell S, Longley MA, Boulter J: α -Fetoprotein and albumin gene expression in brain and other tissues of fetal and adult rats. *Brain Res* 1985;354:49–53.
- 42 Higgins GM, Anderson RM: Experimental pathology of the liver: restoration of the liver of the white rat following partial surgical removal. *AMA Arch Pathol* 1991;139:1352–1368.
- 43 Steiner JW, Pera ZM, Taichman LB: Cell population dynamics in the liver: a review of quantitative morphological techniques applies to the study of physiological and pathological growth. *Exp Mol Pathol* 1966;5:146–181.
- 44 Sell S, Nichols M, Becker FF, Leffert JL: Hepatocyte proliferation and α 1-fetoprotein in pregnant, neonatal and partially hepatectomized rats. *Cancer Res* 1974;34:865–871.
- 45 Sell S: Heterogeneity of α -fetoprotein (AFP) and albumin containing cells in normal and pathological permissive states for AFP production: AFP containing cells induced in adult rats recapitulate the appearance of AFP containing hepatocytes in fetal rats. *OncoDev Biol Med* 1980;1:93–105.
- 46 Engelhardt NV, Lazareva MN, Abelev GI, Uryaeva IV, Factor VM, Brodsky VY: Detection of α -fetoprotein in mouse liver differentiated hepatocytes before their progression through S phase. *Nature* 1976;263:146–148.
- 47 Sell S: The role of liver progenitor cells in repair of liver injury and in liver transplantation. *Wound Repair Regen* 2001;9:467–482.
- 48 Sell S: Heterogeneity and plasticity of hepatocyte lineage cells. *Hepatology* 2001;33:738–750.
- 49 Sell S: Comparison of liver progenitor cells in human atypical ductal reactions with those seen in experimental models of liver injury. *Hepatology* 1998;27:317–331.
- 50 Grisham JW, Porta EA: Origin and fate of proliferated hepatic ductal cells in the rat: electron microscopic and autoradiographic studies. *Exp Mol Pathol* 1964;3:242–261.

- 51 Ruben E: The origin and fate of proliferated bile ductular cells. *Exp Mol Pathol* 1964;3: 279–286.
- 52 Sell S, Reynolds RD, Reutter WJ: Rat α 1-fetoprotein: appearance after galactosamine-induced liver injury. *J Natl Cancer Inst* 1974; 53:289–291.
- 53 Tournier I, Legres L, Schoevaert D, Feldman G, Bernuau D: Cellular analysis of α -fetoprotein gene activation during carbon tetrachloride and D-galactosamine-induced acute liver injury in rats. *Lab Invest* 1998;59: 657–665.
- 54 Petersen BE, Zajec AF, Michalopoulos GK: Hepatic oval cell activation in response to injury following chemically induced periportal of pericentral damage in rats. *Hepatology* 1998;27:1030–1038.
- 55 Yin L, Lynch D, Ilic Z, Sell S: Proliferation and differentiation of ductular liver precursor cells and non-parenchymal cells during the restitutive response of the rat liver to carbon tetrachloride injury after inhibition of hepatocyte proliferation by N-2-acetylaminofluorene. *Histol Histopathol* 2002;17:65–81.
- 56 Lopez M, Mazzanti L: Experimental investigation of alpha-naphthylisothiocyanate as a hyperplastic agent of the biliary ducts in the rat. *J Pathol Bacteriol* 1955;69:243–250.
- 57 Sell S: Comparison of oval cells induced in rat liver by feeding N-2-fluorenylacetamide in a choline devoid diet and bile ducts induced by feeding 4,4'-diaminodiphenylmethane. *Cancer Res* 1983;43:1761–1767.
- 58 Best DH, Coleman WB: Bile duct destruction by 4,4'-diaminodiphenylmethane does not block the small hepatocyte-like progenitor cell response in retrorsine-exposed rats. *Hepatology* 2007;46:1611–1619.
- 59 Yavorkovsky L, Lai E, Ilic Z, Sell S: Participation of small intra-portal stem cells in the restitutive response to periportal injury induced by allyl alcohol. *Hepatology* 1995;21: 1702–1712.
- 60 Sell S: Electron microscopic identification of putative liver stem cells and intermediate hepatocytes following periportal necrosis induced in rats by allyl alcohol. *Stem Cells* 1997;15:378–385.
- 61 Yin L, Lynch D, Sell S: Participation of different cell types in the restitutive response of the rat liver to periportal injury induced by allyl alcohol. *J Hepatol* 1999;31:492–507.
- 62 Rosenberg D, Ilic Z, Sell S: Proliferation of hepatic lineage cells of normal C57BL and IL-6 knockout mice after cocaine-induced periportal injury. *Hepatology* 2000;31:948–955.
- 63 Sell S: Adult stem cell plasticity. *Stem Cell Rev* 2005;1:1–8.
- 64 Thorgerisson SS, Grisham JW: Hematopoietic cells as hepatocyte stem cells: a critical review of the evidence. *Hepatology* 2006;43: 2–8.
- 65 Grompe M, al-Dhalimy M, Finegold M, et al: Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. *Genes Dev* 1993;7:2298–2307.
- 66 Lagasse E, Connors H, Al-Dhalimy M, et al: Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. *Nat Med* 2000;6:1229–1234.
- 67 Vassilopoulos G, Wang PR, Russell DW: Transplanted bone marrow regenerates liver by cell fusion. *Nature* 2003;422:901–904.
- 68 Wang X, Willenbring H, Akkari Y, Torimaru Y, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, Olson S, Grompe M: Cell fusion is the principal source of bone-marrow-derived hepatocytes. *Nature* 2003;422:897–901.
- 69 Vig P, Russo FP, Edwards RJ, Tadrous PJ, Wright NA, Thomas HC, Alison MR, Forbes SJ: The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice. *Hepatology* 2006;43:316–324.
- 70 Petersen BE, Bowen WC, Patrene KD, et al: Bone marrow as a potential source of hepatic oval cells. *Science* 1999;284:1168–1170.
- 71 Oh SH, Witek RP, Bae SH, et al: Bone marrow-derived hepatic oval cells differentiate into hepatocytes in 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration. *Gastroenterology* 2007;132:1077–1087.
- 72 Menthen A, Deb N, Oertel M, et al: Bone marrow progenitors are not the source of expanding oval cells in injured liver. *Stem Cells* 2004;22:1049–1061.
- 73 Moritoki Y, Ueno Y, Kanno N, et al: Lack of evidence that bone marrow cells contribute to cholangiocytic repopulation during experimental cholestatic ductal hyperplasia. *Liver Int* 2006;26:457–466.
- 74 Wulf GG, Luo K-L, Jackson KA, Brenner MK, Goodell MA: Cells of the hepatic side population contribute to liver regeneration and can be replenished by bone marrow stem cells. *J Hematol* 2003;88:368–378.
- 75 Rountree CB, Barsky L, Ge S, Senadheera S, Crooks GM: A CD133 expressing murine liver oval cell population with bi-lineage potential. *Stem Cells* 2007;25:2419–2429.
- 76 Rountree CB, Wang X, Ge S, Barsky L, Zhu J, Gonzales I, Crooks GM: Bone marrow fails to differentiate into liver epithelium during murine development and regeneration. *Hepatology* 2007;45:1250–1260.
- 77 Ochsner SA, Strick-Marchand H, Qiu Q, Venable S, Dean A, Wilde M, Weiss MC, Darlington GJ: Transcriptional profiling of bipotential embryonic liver cells to identify liver progenitor cell surface markers. *Stem Cells* 2007;25:2476–2487.
- 78 Swenson ES, Guest I, Ilic Z, Mazzeo M, Lizardi P, Hardiman C, Sell S, Krause DS: Hepatocyte nuclear factor-1 as a marker of epithelial phenotype reveals marrow-derived hepatocytes, but not duct cells, after liver injury in mice. *Stem Cells* 2008;PMID: 18467658.
- 79 Morris HP, Wagner BP: Induction and transplantation of rat hepatomas with different growth rate (including 'minimal deviation' hepatomas); in Busch H (ed): *Methods in Cancer Research*. New York, Academic Press, 1968, pp 125–152.
- 80 Sell S, Morris HP: Relationship of rat α 1-fetoprotein to growth rate and chromosome composition of Morris hepatomas. *Cancer Res* 1974;34:1413–1417.
- 81 Sell S, Wepsic HT, Nickel R, Nichols M: Rat α 1-fetoprotein IV: the effect of growth and surgical removal of Morris hepatoma 7777 upon the serum α 1-fetoprotein concentrations of Buffalo rats. *J Natl Cancer Inst* 1974; 52:133–137.
- 82 Sell S, Stillman D, Michaelsen M, Alaimo J, VonEssen C: Prevention of pulmonary metastases by irradiation of the lung: a model system employing a transplantable hepatoma and α 1-fetoprotein as an index of tumor growth. *Radiat Res* 1977;69:54–64.
- 83 Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. *Nature* 2001;414:105–111.
- 84 Wicha MS, Liu S, Dontu G: Cancer stem cells: an old idea – a paradigm shift. *Cancer Res* 2006;66:1883–1890.
- 85 Van Wijk T: Regulation of DNA synthesis in cultured rat hepatoma cells. *Int Rev Cytol* 1983;85:63–107.
- 86 Looney WB, Mayo AA, Janners MY, et al: Cell proliferation and tumor growth in hepatoma 3924A. *Cancer Res* 1971;31:821–825.
- 87 Morris HP, Meranze DR: Induction and some characteristics of 'minimal deviation' and other transplantable rat hepatomas. *Recent Results Cancer Res* 1974;44:103–111.
- 88 Kovacs CJ, Evans MJ, Wakefield JA, Looney WB: A comparative study of the response to radiation by experimental tumors with markedly different growth characteristics. *Radiat Res* 1977;72:455–468.
- 89 Potter VR: Recent trends in cancer biochemistry: the importance of studies on fetal tissue. *Proc Can Cancer Conf* 1969;8:9–30.
- 90 Potter VR: Phenotypic diversity in experimental hepatomas; the concept of partially blocked ontogeny. *Br J Cancer* 1978;38:1–23.
- 91 Potter VR: The present status of the blocked ontogeny hypothesis of neoplasia: the Thalassemia connection. *Oncodev Biol Med* 1981;2:243–266.
- 92 Ono T: Enzyme patterns and malignancy of experimental hepatomas. *Gann Monogr Cancer Res* 1966;1:189–206.
- 93 Sugimura T, Matsushima T, Kawachi T, Hirata Y, Kawabe S: Molecular species of aldolases and hexokinases in experimental hepatomas. *Gann Monogr Cancer Res* 1966;1: 143–150.
- 94 Schapira F: Aldolase isozymes in cancer. *Eur J Cancer* 1966;2:131–134.

- 95 Matsushima T, Kawabe S, Shibuya M, Sugimura T: Aldolase isozyme in rat tumor cells. *Biochem Biophys Res Commun* 1968; 30:565–570.
- 96 Farber E: On the concept of minimal deviation in the study of the biochemistry of cancer. *Cancer Res* 1968;28:1210–1211.
- 97 Sell S: Diagnostic applications of α -fetoprotein: government regulations prevent full application of a clinically useful test. *Hum Pathol* 1981;12:959–963.
- 98 Sell S: Stem cells in hepatocarcinogenesis. *Cell Sci Rev* 2006;3:302–341.
- 99 Yoshida T: o-Aminoazotoluol: Über die experimentelle annulare Lebercirrhose des Kaninchens. *Trans Jpn Pathol Soc* 1935;25: 409–411.
- 100 Kinoshita R: Special report: studies on the cancerogenic chemical substances. *Trans Jpn Pathol Soc* 1937;27:655–725.
- 101 Orr JW: The histology of the rat's liver during the course of carcinogenesis by buttyellow (p-dimethylaminoazobenzene). *J Pathol Bacteriol* 1940;50:393–408.
- 102 Opie EL: The pathogenesis of tumors of the liver produced by buttyellow. *J Exp Med* 1944;80:231–246.
- 103 Farber E: Similarities in the sequence of early histologic changes induced in the liver by ethionine, 2-acetylaminofluorene, and 3'-methyl-4-dimethylaminoazobenzene. *Cancer Res* 1956;16:142–148.
- 104 Farber E, Sarma DSR: Hepatocarcinogenesis: a dynamic cellular perspective. *Lab Invest* 1987;56:4–22.
- 105 Pitot HC: The natural history of neoplastic development: the relation of experimental models to liver cancer. *Cancer* 1982;49: 1206–1211.
- 106 Scherer E: Neoplastic progression in experimental hepatocarcinogenesis. *Biochim Biophys Acta* 1984;738:219–236.
- 107 Rabes HM: Development and growth of early preneoplastic lesions induced in the liver by chemical carcinogens. *J Cancer Res Clin Oncol* 1983;106:85–91.
- 108 Bannasch P: Sequential cellular changes during chemical carcinogenesis. *J Cancer Res Clin Oncol* 1984;108:11–22.
- 109 Bannasch P, Hacker HJ, Klinef F, Mayer D: Hepatocellular glycogenesis and related pattern of enzymatic changes during hepatocarcinogenesis. *Adv Enzyme Regul* 1984; 22:97–121.
- 110 Aterman KJ: The stem cells of the liver – a selective review. *Cancer Clin Oncol* 1992; 118:87–115.
- 111 Becker FF, Sell S: Differences in serum α -fetoprotein concentrations during the carcinogenic sequences resulting from exposure to diethylnitrosamine or acetylaminofluorene. *Cancer Res* 1979;39:1437–1442.
- 112 Teebor GW, Becker FF: Regression and persistence of hyperplastic hepatic nodules induced by N-2-fluorenylacetylamide and their relationship to hepatocarcinogenesis. *Cancer Res* 1971;31:1–3.
- 113 Sell S: Distribution of α -fetoprotein and albumin containing cells in the livers of Fisher rats fed four cycles of N-2-fluorenylacetylamide. *Cancer Res* 1978;75:181–186.
- 114 Sell S, Leffert HL: An evaluation of cellular lineages in the pathogenesis of experimental hepatocellular carcinoma. *Hepatology* 1982;2:77–86.
- 115 Shinozuka H, Lombardi B, Sell S, Iammarino RM: Modification of ethionine liver carcinogenesis by choline deficiency: early histological and functional alterations. *Cancer Res* 1978;38:1092–1098.
- 116 Shinozuka H, Lombardi B, Sell S, Iammarino RM: Enhancement of DL-ethionine-induced liver carcinogenesis in rats fed a choline devoid diet. *J Natl Cancer Inst* 1978; 61:813–818.
- 117 Sell S, Osborn K, Leffert HL: Autoradiography of 'oval cells' appearing early in the livers of rats fed N-2-fluorenylacetylamide in choline devoid diet. *Carcinogenesis* 1981;2: 7–14.
- 118 Sell S, Salman J: Light and electronmicroscopic autoradiographic analysis of proliferating cells during the early stages of chemical hepatocarcinogenesis in the rat induced by feeding N-2-fluorenylacetylamide in a choline deficient diet. *Am J Pathol* 1984;114:287–300.
- 119 Solt DB, Farber E: New principle for the analysis of chemical carcinogenesis. *Nature* 1976;263:702–703.
- 120 Sell S, Dunsford H: Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. *Am J Pathol* 1989; 134:1347–1363.
- 121 Dunsford A, Maset R, Salman J, Sell S: Connection of ductlike structures induced by a chemical hepatocarcinogen to portal bile ducts in the rat liver detected by injection of bile ducts with a pigmented barium gelatin medium. *Am J Pathol* 1985;118:218–224.
- 122 Sell S: The role of determined stem-cells in the cellular lineage of hepatocellular carcinoma. *Int J Dev Biol* 1993;33:189–201.
- 123 Schmidt D, Harms D, Lang W: Primary hepatic tumours in childhood. *Virchows Arch A Pathol Anat Histopathol* 1985;407: 387–405.
- 124 Kasai M, Watanabe I: Histologic classification of liver cell carcinoma in infancy and childhood and its clinical evaluation. *Cancer* 1970;25:551–563.
- 125 Haas R, Muczynski KA, Krailo M, et al: Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. *Cancer* 1989;64:1082–1095.
- 126 Sell S, Pierce GB: Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. *Lab Invest* 1994;70: 6–21.
- 127 Moro R, Tanaoki T, Wegmann TG, Longnecker BM, Laderoute MP: Monoclonal antibodies directed against a sidespread oncofetal antigen: the α -fetoprotein receptor. *Tumour Biol* 1993;14:116–130.
- 128 Sonnenschein C, Soto AM: Growth inhibition of estrogen-sensitive tumor cells in newborn rats: probable role of α -fetoprotein. *J Natl Cancer Inst* 1979;63:835–841.
- 129 Sonnenschein D, Ucci A, Soto AM: Growth inhibition of estrogen-sensitive rat mammary tumors: effect of an α -fetoprotein-secreting hepatoma. *J Natl Cancer Inst* 1980; 64:1147–1152.
- 130 Bennett JA, Mesfin FB, Andersen TT, Gierthy JF, Jacobson HI: A peptide derived from α -fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen. *Proc Natl Acad Sci* 2002;99:2211–2215.
- 131 Recamier JCA: Recherches sur le traitement du cancer: par la compression methodique simple ou combinee, et sur l'histoire general de la meme maladie. Paris, Gabon, 1829.
- 132 Remark R: Ein Beitrag zur Entwicklungsgeschichte der krebshaften Geschwulste. *Dtsch Klin* 1854;6:70–174.
- 133 Virchow R: Die krankhaften Geschwülste. Berlin, Hirschwald, 1863.
- 134 Durante F: Nesso fisio-pathologico tra la struttura dei nei materni e la genesi di alcuni tumori maligni. *Arch Memor Osserv Chir Pract* 1874;11:217–226.
- 135 Cohnheim J: Congenitales, quergestreiftes Muskelsarkom der Nieren. *Virchows Arch* 1875;65:64.
- 136 Bainbridge WS: The Cancer Problem. New York, Macmillan, 1914.
- 137 Peyron A: Sur la présence des cellules génitales primordiales dans les boutons embryonnaires des embryones parthenogénétiques chez l'homme. *CR Acad Sci (Paris)* 1938;206:1680–1683.
- 138 Braunstein GD, McIntire KR, Waldmann TA: Discordance of human chorionic gonadotropin and α -fetoprotein in testicular teratocarcinomas. *Cancer* 1973;31:1065–1068.
- 139 Willemse PHB, Sleijfer DT, Schraffordt Koops H, De Bruijn HWA, Oosterhuis JW, Brouwers TM, Ockhuizen T, Marrink J: Tumor markers in patients with non-seminomatous germ cell tumors of the testis. *Oncodev Biol Med* 1981;2:117–128.
- 140 Vogelzang NJ, Lange PH, Goldman A, Vesela RH, Fraley EE, Kennedy BJ: Acute changes of α -fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. *Cancer Res* 1982;42:4855–4861.
- 141 Stevens LE, Little CC: Spontaneous testicular teratomas in inbred strains of mice. *Proc Natl Acad Sci USA* 1954;40:1080–1087.
- 142 Stevens LC: Origin of testicular teratomas from primordial germ cells in mice. *J Natl Cancer Inst* 1967;38:549–552.

- 143 Stevens LC: Experimental production of testicular teratomas in mice. *Proc Natl Acad Sci USA* 1964;52:654–661.
- 144 Rippert V: *Das Carcinoma des Menschen, Geschwulstlehre*. Bonn, 1911.
- 145 Damjanov I, Skreb N, Sell S: Origin of embryo-derived yolk sac carcinomas. *Int J Cancer* 1977;19:526–530.
- 146 Pierce GB, Dixon FL, Varney EL: Teratocarcinogenic and tissue forming potentials of the cell types comprising neoplastic embryo bodies. *Lab Invest* 1960;9:583–602.
- 147 Pierce GB, Wallace C: Differentiation of malignant cells to benign cells. *Cancer Res* 1971;31:127–124.
- 148 Brinster RL: Effect of cells transferred into the mouse blastocyst on subsequent development. *J Exp Med* 1974;140:1049–1056.
- 149 Mintz B, Illmensee K: Normal genetically mosaic mice produced from malignant teratocarcinoma cells. *Proc Natl Acad Sci USA* 1975;72:3583–3589.
- 150 Papaioannou VE, McBurndy MW, Gardner RL, Evans MJ: Fate of teratocarcinoma cells injected into early mouse embryos. *Nature* 1975;258:70–73.
- 151 Pierce GB, Arechaga J, Jones A, Lewellyn A, Wells RS: The fate of embryonal-carcinoma cells in mouse blastocysts. *Differentiation* 1987;33:247–253.
- 152 Pierce GB, Spears WC: Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. *Cancer Res* 1988;48:1196–1204.
- 153 Yoshitake T, Itoyama S: Treatment of primary mediastinal germ cell tumors. *Tinsho Kyobu Geka* 1989;9:29–34.
- 154 Sell S: Stem cell origin of cancer and differentiation therapy. *Crit Rev Oncol Hematol* 2004;51:1–28.
- 155 Sell S: Potential gene therapy strategies for cancer stem cells. *Curr Gene Ther* 2006;6:579–591.
- 156 Sell S: Cancer and stem cell signaling: a guide to preventive and therapeutic strategies for cancer stem cells. *Stem Cell Rev* 2007;3:1–6.
- 157 Sell S: Leukemia: stem cells, maturation arrest, and differentiation therapy. *Stem Cell Rev* 2005;1:197–205.
- 158 Sell S: Cancer stem cells and differentiation therapy. *Tumor Biol* 2006;27:59–70.
- 159 Drucker BJ, Guilhot F, O'Brian SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *N Engl J Med* 2006;355:2408–2417.
- 160 Segalla S, Rinaldi L, Kilstrup-Nielsen C, Badaracco G, et al: Retinoic acid receptor α fusion to PML affects in transcriptional and chromatin-remodeling properties. *Mol Cell Biol* 2003;23:8795–8808.
- 161 Pitha-Rowe I, Petty WJ, Kitareewan S, Dmitrovsky E: Retinoid target genes in acute promyelocytic leukemia. *Leukemia* 2003;17:1723–1730.
- 162 Chalandon Y, Schwaller J: Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies. *Haematologica* 2005;90:949–968.
- 163 Gilliland DG, Griffin JD: The role of FLT3 in hematopoiesis and leukemia. *Blood* 2002;100:1332–1342.
- 164 Feldman EJ: Farnesyltransferase inhibitors in melanodysplastic syndrome. *Curr Hematol Rep* 2004;4:186–190.
- 165 Puck TT, Marcus PI: A rapid method of viable cell titration and clone production with HeLa cells in tissue culture: use of x-irradiated cells to supply conditioning factors. *Proc Natl Acad Sci USA* 1955;41:432–437.
- 166 Buick RN: In vitro clonogenicity of primary human tumor cells: quantitation and relationship to tumor stem cells; in Salmon S (ed): *Cloning of Human Tumor Stem Cells*. New York, AR Liss, 1980, pp 15–20.
- 167 Salmon S: In vitro effects of drugs on human tumor stem cell assays; in Salmon S (ed): *Cloning of Human Tumor Stem Cells*. New York, AR Liss, 1980, pp 197–312.
- 168 Greene HSN: The significance of the heterogeneous translatability of human cancer. *Cancer* 1952;5:24–44.
- 169 Reinhard MC, Goltz HL, Warner SC: Further studies on the quantitative determination of the growth of a transplantable mouse adenocarcinoma. *Cancer Res* 1952;12:102–106.
- 170 Hewitt HB: Transplantation of mouse sarcomas with small numbers of single cells. *Nature* 1952;170:622–623.
- 171 Lapidot T, Sirard C, Bormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature* 1994;367:645–648.
- 172 Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med* 1997;3:730–737.
- 173 Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MR: Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci USA* 2003;100:3983–3988.
- 174 Lee J-S, Heo J, Libbrecht L, Chu I-N, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun A, Nevens F, Roskams T, Thorgeirsson SS: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. *Nat Med* 2006;12:410–416.
- 175 Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ce C, Xie H, Wan D, Yang S, Zheng S, Gu J: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. *Int J Cancer* 2007;120:1444–1450.
- 176 Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. *Gastroenterology* 2007;132:2542–2556.
- 177 Ma S, Lee TK, Zheng B-J, Chan KW, Guan X-Y: CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. *Oncogene* 2008;27:1749–1758.
- 178 Yang ZF, Ngai P, Ho DW, Yu WC, Ng MNP, Lau CK, Li MLY, Tam KO, Lam CT, Poon RTP, Fan ST: Identification of local and circulating cancer stem cells in human liver cancer. *Hepatology* 2008;47:919–928.
- 179 Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PEK, Lan CT, Poon RTP, Fan ST: Significance of CD90+ cancer stem cells in human liver cancer. *Cancer Cell* 2008;13:153–166.
- 180 Zen Y, Fujii T, Yoshikawa S, Takamura H, Tani T, Ohtia T, Nakanuma Y: Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. *Am J Pathol* 2007;170:1750–1762.
- 181 Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budu A, Zanetti KA, Chen Y, Qin L-X, Tang Z-Y, Wang XW: EpCAM and α -fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. *Cancer Res* 2008;68:1451–1461.
- 182 Kaposi-Novak P, Lee J-S, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS: Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. *J Clin Invest* 2006;116:1582–1595.
- 183 Trott KR: Tumour stem cells: the biological concept and its application in cancer treatment. *Radiother Oncol* 1994;30:1–5.
- 184 Denekamp J: Tumour stem cells: facts, interpretation and consequences. *Radiother Oncol* 1994;30:6010.
- 185 Rich JN: Cancer stem cells in radiation resistance. *Cancer Res* 2007;67:8980–8984.
- 186 Cairns J: Somatic stem cells and the kinetics of mutagenesis and carcinogenesis. *Proc Natl Acad Sci USA* 2002;99:10567–10570.
- 187 Cairns J: Cancer and the immortal strand hypothesis. *Genetics* 2006;174:1069–1072.
- 188 Sell S: Cancer and stem cell signaling: a guide to preventive and therapeutic strategies for cancer stem cells. *Stem Cell Rev* 2007;3:1–6.